Initial safety analysis of a randomized phase II trial of nelipepimut-S + GM-CSF and trastuzumab compared to trastuzumab alone to prevent recurrence in breast cancer patients with HER2 low-expressing tumors

Autor: Clifton, G. Travis, Peace, Kaitlin M., Holmes, Jarrod P., Vreeland, Timothy J., Hale, Diane F., Herbert, Garth S., Litton, Jennifer K., Murthy, Rashmi K., Lukas, Jason, Peoples, George E., Mittendorf Elizabeth, A.
Zdroj: In Clinical Immunology April 2019 201:48-54
Databáze: ScienceDirect
Externí odkaz: